Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma
Status:
Recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
This is an open-labelled single arm trial of pembrolizumab and imatinib mesylate in subjects
with unresectable or metastatic KIT-mutant melanoma that are refractory to standard therapy.
The phase Ib and II study will be conducted to evaluate the safety, tolerability and response
rate data of this combination therapy. KIT-mutant tumors will be confirmed in previously
biopsied tumors. This analysis will be done by next-generation sequencing.